|
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.
Considerations:
- Revenue-generating biosciences company focused on improving the delivery of active pharmaceutical ingredients into the bloodstream
- Proprietary technology shown to enhance the bioavailability of orally ingested cannabinoids while improving the taste
- Actively developing and selling hemp oil-based consumer products through Lexaria’s brands ViPova™, TurboCBD and ChrgD+
- Partnership with one of the world’s largest cigarette companies provides up to US$12 million in funding for clinical investigations and product development conducted by Lexaria Nicotine LLC to explore oral forms of nicotine delivery using the Company’s patented DehydraTECH technology
- One of the world’s largest patent portfolios related to oral delivery of molecules such as cannabinoids, nicotine and more. This patent portfolio reasonably expected to grow even stronger
|
